| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 11, 2024 4:00 P.M. |
| Form: | F-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
First patient in Cohort B achieved CR after 2nd dose of TCB008EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC (NASDAQ:TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable Minimal Residual Disease (MRD), is now in complete molecular remission following treatment with the lead drug candidate TCB008. The response was achieved after the patient's second dose of 250,000,000 gamma delta t-cells, two weeks after
EDINBURGH, Scotland, March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on March 20, 2025, it received notice that the Nasdaq Hearings Panel had determined to delist the Company's securities from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed securities to maintain a minimum bid price of $1.00 per share. Management is currently working on an appeal with Nasdaq.
The company is expected to reduce core operational burn by 55% when compared to 2024EDINBURGH, Scotland, March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced initiatives to outsource several functions, moving to a more decentralized model, resulting in reduction in its workforce and creating a leaner and more agile organization as part of the company's strategic developmental plan.
4 - TC BioPharm (Holdings) plc (0001872812) (Issuer)
4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)
4/A - TC BioPharm (Holdings) plc (0001872812) (Issuer)
6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)
6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)
6-K - TC BioPharm (Holdings) plc (0001872812) (Filer)
EDINBURGH, Scotland, Feb. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Dr. Michael Leek to the position of Chief Technology Officer. Dr. Leek resumes operational duties as CTO after stepping down as executive chairman of the board. With more than 35 years experience in cell-based research and development, Co-founder, Michael Leek, Ph.D., had previously served as TC BioPharm's Exec
EDINBURGH, Scotland, Feb. 14, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Arlene M. Morris to the position of Chair of the Board. Ms. Morris has held a seat on the TC BioPharm board as an independent director since 2022. An accomplished biotech executive and board member, with many years of experience, Ms. Morris has a proven track record of evolving businesses and en
Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the appointment of Bree Harlin as Chief Clinical Officer (CCO), effective immediately. Ms. Harlin brings more than twenty years of experience in research, oncology and clinical stage drug development to TC BioPharm. Most recently she was with Loxo at Lilly, where
In the news release, TCBP Issues 25% Stock Dividend, issued 30-Dec-2024 by TC BioPharm over PR Newswire, we are advised by the company that in the fourth paragraph, both instances of "January 8" should instead read "January 7". The complete, corrected release follows: TCBP Issues 25% Stock Dividend EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend.
EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares ("ADSs") for every 1 ADS he
EDINBURGH, Scotland, Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders, pending shareholder approval. The Company intends to hold a general meeting of shareholders ("GM") at 2:00 p.m. (UK time) on Monday, December 30, 2024, at The Seafield Arms Hotel, 17-19 Seafield St, Cullen, Buckie AB56 4SH, Scotland, United Kingdom.
SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)
SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)
SC 13G/A - TC BioPharm (Holdings) plc (0001872812) (Subject)